Therapeutic efficacy and safety of venetoclax

Venetoclaxis an oral targeted therapy drug. It is the world's first drug that selectively targets B-cell lymphoma-2 (BCL-2) protein. The main mechanism of action of venetoclax is to restore the normal apoptosis process of cells by inhibiting the function of BCL-2 protein, thereby killing tumor cells in a targeted manner. This drug has shown significant efficacy in the treatment of certain hematological malignancies, particularly chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML).

In the treatment of CLL and SLL, venetoclax can be administered alone or in combination with obinutuzumab or rituximab, showing high efficacy. For newly diagnosed AML patients, especially those who are not suitable for intensive induction chemotherapy due to comorbidities, or those aged 75 years and above, the combination treatment regimen of venetoclax and azacitidine has proven to be an effective treatment.

Regarding safety, although venetoclax has been well tolerated in clinical applications, patients may still experience some adverse reactions. Common adverse reactions include nausea, diarrhea, neutropenia, thrombocytopenia, etc. Most of these reactions are mild to moderate and can usually be controlled and relieved with appropriate medical management. In order to ensure patient safety, doctors will evaluate the patient's specific situation when prescribing Venexacla and make close monitoring and adjustments during the treatment process.

Overall, venetoclax, as an innovative targeted therapy, has demonstrated significant efficacy in the treatment of a variety of hematological tumors. When used under the guidance and monitoring of doctors, its safety is guaranteed, providing new treatment options and hope for many patients.